keyword
MENU ▼
Read by QxMD icon Read
search

parkinson plus

keyword
https://www.readbyqxmd.com/read/28432010/exposure-to-an-enriched-environment-facilitates-motor-recovery-and-prevents-short-term-memory-impairment-and-reduction-of-striatal-bdnf-in-a-progressive-pharmacological-model-of-parkinsonism-in-mice
#1
Clarissa L C Campêlo, José R Santos, Anatildes F Silva, Aline L Dierschnabel, André Pontes, Jeferson S Cavalcante, Alessandra M Ribeiro, Regina H Silva
Previous studies showed that the repeated administration with a low dose of reserpine (RES) induces a gradual appearance of motor signs and cognitive deficits compatible with parkinsonism in rodents. Environmental stimulation has neuroprotective effects in animal models of neurodegenerative damage, including acutely induced PD. We investigated the effects of exposure to an enriched environment (EE) on motor, cognitive and neuronal (levels of tyrosine hydroxylase, TH and brain derived neurotrophic factor, BDNF) deficits induced by a progressive model of PD in mice...
April 18, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28420370/neuroprotective-effect-of-demethoxycurcumin-a-natural-derivative-of-curcumin-on-rotenone-induced-neurotoxicity-in-sh-sy-5y-neuroblastoma-cells
#2
Muthu Ramkumar, Srinivasagam Rajasankar, Veerappan Venkatesh Gobi, Chinnasamy Dhanalakshmi, Thamilarasan Manivasagam, Arokiasamy Justin Thenmozhi, Musthafa Mohamed Essa, Ameer Kalandar, Ranganathan Chidambaram
BACKGROUND: Mitochondrial dysfunction and oxidative stress are the main toxic events leading to dopaminergic neuronal death in Parkinson's disease (PD) and identified as vital objective for therapeutic intercession. This study investigated the neuro-protective effects of the demethoxycurcumin (DMC), a derivative of curcumin against rotenone induced neurotoxicity. METHODS: SH-SY5Y neuroblastoma cells are divided into four experimental groups: untreated cells, cells incubated with rotenone (100 nM), cells treated with DMC (50 nM) + rotenone (100 nM) and DMC alone treated...
April 18, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28379218/further-pharmacological-characterization-of-eltoprazine-focus-on-its-anxiolytic-anorexic-and-adverse%C3%A2-effect-potential
#3
Andreas Gravius, Andrzej Dekundy, Anita Vanaga, Lutz Franke, Wojciech Danysz
Eltoprazine, a drug that had previously been developed for aggression, has recently been investigated for L-DOPA-induced dyskinesia in animal models of Parkinson´s disease (PD) and in dyskinetic PD patients. Much less is known about effects of eltoprazine in other therapeutic indications. Indeed, the pharmacological profile of eltoprazine might suggest its effects on anxiety and food intake, but also adverse effect potential, which is the focus of the present study. Given for 2 weeks either as infusion or as twice-daily treatment, eltoprazine produced a decrease in food intake and body weight at doses leading to 200-500 nM plasma concentrations...
2017: Acta Neurobiologiae Experimentalis
https://www.readbyqxmd.com/read/28373840/promising-effects-of-neurorestorative-diets-on-motor-cognitive-and-gastrointestinal-dysfunction-after-symptom-development-in-a-mouse-model-of-parkinson-s-disease
#4
Paula Perez-Pardo, Esther M de Jong, Laus M Broersen, Nick van Wijk, Amos Attali, Johan Garssen, Aletta D Kraneveld
Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic nigrostriatal neurons, with reductions in the function and amount of dopaminergic synapses. Therefore, synapse loss and membrane-related pathology provide relevant targets for interventions in PD. We previously showed the beneficial preventive effects of a dietary intervention containing uridine and DHA, two precursors for membrane synthesis, in the intrastriatal rotenone model for PD. Here, we examined the therapeutic potential of the same dietary intervention on motor, cognitive, and gastrointestinal symptoms...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28370447/trial-of-dextromethorphan-quinidine-to-treat-levodopa-induced-dyskinesia-in-parkinson-s-disease
#5
Susan H Fox, Leonard Verhagen Metman, John G Nutt, Matthew Brodsky, Stewart A Factor, Anthony E Lang, Laura E Pope, Nadine Knowles, João Siffert
BACKGROUND: Nondopaminergic pathways represent potential targets to treat levodopa-induced dyskinesia in Parkinson's disease (PD). This pilot-study (NCT01767129) examined the safety/efficacy of the sigma-1 receptor-agonist and glutamatergic/monoaminergic modulator, dextromethorphan plus quinidine (to inhibit rapid dextromethorphan metabolism), for treating levodopa-induced dyskinesia. METHODS: PD patients were randomized to dextromethorphan/quinidine (45 mg/10 mg twice daily)/placebo in two 2-week double-blind, crossover treatment periods, with intervening 2-week washout...
March 30, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28370314/statins-may-facilitate-parkinson-s-disease-insight-gained-from-a-large-national-claims-database
#6
Guodong Liu, Nicholas W Sterling, Lan Kong, Mechelle M Lewis, Richard B Mailman, Honglei Chen, Douglas Leslie, Xuemei Huang
OBJECTIVE: Using a large U.S. claims database (MarketScan), we investigated the controversy surrounding the role of statins in Parkinson's disease (PD). METHODS: We performed a retrospective case-control analysis. First, we identified 2322 incident PD cases having a minimum of 2.5 years of continuous enrollment prior to earliest diagnosis code or prescription of antiparkinson medication. A total of 2322 controls were then matched individually by age, gender, and a follow-up window to explore the relationship of statin use with incident PD...
April 3, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28360997/imaging-biomarkers-in-parkinson-s-disease-and-parkinsonian-syndromes-current-and-emerging-concepts
#7
REVIEW
Usman Saeed, Jordana Compagnone, Richard I Aviv, Antonio P Strafella, Sandra E Black, Anthony E Lang, Mario Masellis
Two centuries ago in 1817, James Parkinson provided the first medical description of Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to include the atypical parkinsonian variants (also termed, Parkinson-plus syndromes). Today, Parkinson's disease represents the second most common neurodegenerative disorder with an estimated global prevalence of over 10 million. Conversely, atypical parkinsonian syndromes encompass a group of relatively heterogeneous disorders that may share some clinical features with Parkinson's disease, but are uncommon distinct clinicopathological diseases...
2017: Translational Neurodegeneration
https://www.readbyqxmd.com/read/28342967/the-effects-of-omega-3-fatty-acids-and-vitamin-e-co-supplementation-on-clinical-and-metabolic-status-in-patients-with-parkinson-s-disease-a-randomized-double-blind-placebo-controlled-trial
#8
Mohsen Taghizadeh, Omid Reza Tamtaji, Ehsan Dadgostar, Reza Daneshvar Kakhaki, Fereshteh Bahmani, Javad Abolhassani, Mohammad Hossein Aarabi, Ebrahim Kouchaki, Mohammad Reza Memarzadeh, Zatollah Asemi
The current research was performed to evaluate the effects of omega-3 fatty acids and vitamin E co-supplementation on clinical signs and metabolic status in people with Parkinson's disease (PD). This randomized double-blind placebo-controlled clinical trial was conducted in 60 patients with PD. Participants were randomly assigned into two groups to receive either 1000 mg omega-3 fatty acids from flaxseed oil plus 400 IU vitamin E supplements (n = 30) or placebo (n = 30) for 12 weeks. Unified Parkinson's disease rating stage (UPDRS) were recorded at baseline and the after 3-month intervention...
March 22, 2017: Neurochemistry International
https://www.readbyqxmd.com/read/28264233/striatal-glutamate-and-gaba-after-high-frequency-subthalamic-stimulation-in-parkinsonian-rat
#9
Kyung Jin Lee, Insop Shim, Jae Hoon Sung, Jae Taek Hong, Il Sup Kim, Chul Bum Cho
OBJECTIVE: High frequency stimulation (HFS) of the subthalamic nucleus (STN) is recognized as an effective treatment of advanced Parkinson's disease. However, the neurochemical basis of its effects remains unknown. The aim of this study is to investigate the effects of STN HFS in intact and 6-hydroxydopamine (6-OHDA)-lesioned hemiparkinsonian rat model on changes of principal neurotransmitters, glutamate, and gamma-aminobutyric acid (GABA) in the striatum. METHODS: The authors examined extracellular glutamate and GABA change in the striatum on sham group, 6-OHDA group, and 6-OHDA plus deep brain stimulation (DBS) group using microdialysis methods...
March 2017: Journal of Korean Neurosurgical Society
https://www.readbyqxmd.com/read/28254636/land-plus-aquatic-therapy-versus-land-based-rehabilitation-alone-for-the-treatment-of-balance-dysfunction-in-parkinson-disease-a-randomized-controlled-study-with-6-month-follow-up
#10
Grazia Palamara, Francesco Gotti, Roberto Maestri, Rossana Bera, Roberto Gargantini, Fabiola Bossio, Ilaria Zivi, Daniele Volpe, Davide Ferrazzoli, Giuseppe Frazzitta
OBJECTIVES: To assess whether a specific land-based physical intervention with the inclusion of aquatic therapy is more effective than land-based rehabilitation alone for the treatment of balance dysfunction in patients with Parkinson disease (PD), immediately after therapy and at 6 months' follow-up. DESIGN: Randomized controlled study with 6-month follow-up. SETTING: A PD and brain injury rehabilitation department in a general hospital. PARTICIPANTS: Patients (N=34) with moderate-stage PD...
February 27, 2017: Archives of Physical Medicine and Rehabilitation
https://www.readbyqxmd.com/read/28250027/predictors-of-survival-in-progressive-supranuclear-palsy-and-multiple-system-atrophy-a-systematic-review-and-meta-analysis
#11
Stella Andrea Glasmacher, Peter Nigel Leigh, Romi Anirban Saha
OBJECTIVE: To undertake a systematic review and meta-analysis of studies that investigated prognostic factors and survival in patients with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). METHODS: Publications of at least 10 patients with a likely or confirmed diagnosis of PSP or MSA were eligible for inclusion. Methodological quality was rated using a modified version of the Quality in Prognostic Studies tool. For frequently examined prognostic factors, HRs derived by univariate and multivariate analysis were pooled in separate subgroups; other results were synthesised narratively and HRs could not be reported here...
March 1, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28249117/anti-inflammatory-and-neuroprotective-activity-of-boswellic-acids-in-rotenone-parkinsonian-rats
#12
Angie Ameen, Amany Elkazaz, Hala M F A Mohammad, Bassant Mohamed Barakat
There is evidence that inflammation and oxidative stress contribute to neurodegenerative changes observed in Parkinson's disease (PD). Unfortunately, there is a lack of curative treatments for this debilitating movement disorder. Boswellic acids (BAs) are pentacyclic triterpene molecules of plant origin and have been utilized for treating many inflammatory conditions. The current study was conducted to explore the role of BAs in protection from rotenone-induced experimental Parkinsonism. Twenty four rats were assigned as vehicle group, rotenone control group: rats received rotenone (1 mg/kg) every 48...
March 1, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28187263/tetrahydroxystilbene-glucoside-inhibits-%C3%AE-synuclein-aggregation-and-apoptosis-in-a53t-%C3%AE-synuclein-transfected-cells-exposed-to-mpp-sup-sup
#13
Ruyi Zhang, Fangling Sun, Lan Zhang, Xuejing Sun, Lin Li
Increasing evidence has solidified the involvement of α-synuclein (α-Syn) and neurotoxins in the pathogenesis of Parkinson's disease (PD), suggesting a combination of genetic and environmental influences. 2,3,5,4'-Tetrahydroxystilbene -2-O-β-D-glucoside (TSG) is one of the main active components extracted from Polygonum multiflorum. The purpose of the present study was to investigate the effects of TSG on α-Syn aggregation, mitochondrial dysfunction, oxidative stress and apoptosis in vitro. A53T mutant α-synuclein-transfected cells (A53T AS cells) plus MPP+<sup></sup> exposure were used as a complex cell model of PD...
February 10, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28167456/antidepressant-and-anxiolytic-like-activity-of-sodium-selenite-after-acute-treatment-in-mice
#14
Ewa Kędzierska, Jarosław Dudka, Ewa Poleszak, Jolanta H Kotlińska
BACKGROUND: Selenium (Se) is an essential trace element for humans and animals, that is needed for a broad variety of physiological functions including thyroid hormone metabolism, protection against oxidative stress, and immunity associated functions. Human nutritional Se deficiencies are associated with neuropsychiatric diseases, like Alzheimer's disease, Parkinson's disease, obsessive - compulsive disorder, stroke, epilepsy as well as depressive behaviours. In this study we examined antidepressant- and anxiolytic-like activity of Se in the inorganic form of sodium selenite and investigated whether Se influence on the locomotor activity in mice...
April 2017: Pharmacological Reports: PR
https://www.readbyqxmd.com/read/28158197/rehabilitation-in-progressive-supranuclear-palsy-effectiveness-of-two-multidisciplinary-treatments
#15
Ilaria Clerici, Davide Ferrazzoli, Roberto Maestri, Fabiola Bossio, Ilaria Zivi, Margherita Canesi, Gianni Pezzoli, Giuseppe Frazzitta
BACKGROUND: to date, there are no medical or surgical treatments for progressive supranuclear palsy (PSP). It is possible to speculate that patients with PSP could benefit from rehabilitative treatments designed for Parkinson's disease, including the use of robot-assisted walking training. OBJECTIVE: to evaluate whether the use of the robotic device Lokomat® is superior in PSP patients to the use of treadmill with visual cues and auditory feedbacks (treadmill-plus) in the context of an aerobic, multidisciplinary, intensive, motor-cognitive and goal-based rehabilitation treatment (MIRT) conceived for Parkinsonian patients...
2017: PloS One
https://www.readbyqxmd.com/read/28146614/tardive-dyskinesia-prevalence-in-the-period-of-second-generation-antipsychotic-use-a-meta-analysis
#16
Maren Carbon, Cheng-Hsi Hsieh, John M Kane, Christoph U Correll
OBJECTIVE: Comparison of tardive dyskinesia (TD) prevalence during contemporaneous treatment with first-generation antipsychotics (FGAs) and/or second-generation antipsychotics (SGAs). DATA SOURCES: PubMed/MEDLINE/Google Scholar search (January 1, 2000-September 30, 2015) without language restriction using (tardive dyskinesia OR tardive) AND (antipsychotic*) plus specific names of SGAs. STUDY SELECTION: Of 8,895 hits, we screened 203 full-text articles for cross-sectional, rating scale-based TD rates during SGA, FGA, or FGA+SGA treatment...
January 31, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28131167/conversion-to-carbidopa-and-levodopa-extended-release-ipx066-followed-by-its-extended-use-in-patients-previously-taking-controlled-release-carbidopa-levodopa-for-advanced-parkinson-s-disease
#17
James Tetrud, Paul Nausieda, David Kreitzman, Grace S Liang, Anette Nieves, Andrew P Duker, Robert A Hauser, Eric S Farbman, Aaron Ellenbogen, Ann Hsu, Sherron Kell, Sarita Khanna, Robert Rubens, Suneel Gupta
BACKGROUND: IPX066 (Rytary®; carbidopa and levodopa [CD-LD] extended-release capsules) was designed to achieve therapeutic LD plasma concentrations within 1h of dosing and maintain LD concentrations for a prolonged duration in early or advanced Parkinson's disease (PD). METHODS: In this open-label study, patients underwent 6weeks of conversion to IPX066 from their prior controlled-release (CR)±immediate-release (IR) CD-LD therapy and 6months of maintenance (with an additional 6months of IPX066 at some sites)...
February 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28125950/fall-related-healthcare-use-and-costs-in-neurogenic-orthostatic-hypotension-with-parkinson-s-disease
#18
Clement François, Italo Biaggioni, Cyndya Shibao, Augustina Ogbonnaya, Huai-Che Shih, Eileen Farrelly, Adam Ziemann, Amy Duhig
AIMS: To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH). MATERIALS AND METHODS: MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-December 31, 2013) were used to identify PD and probable PD + nOH patients. The first medical or prescription claim suggesting these diagnoses served as the index date...
February 6, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28123558/neuroprotective-effect-of-matrine-on-mptp-induced-parkinson-s-disease-and-on-nrf2-expression
#19
Fanhua Meng, Jianhui Wang, Fuxiang Ding, Yunliang Xie, Yingjie Zhang, Jie Zhu
The incidence rate of Parkinson's disease (PD) is ≤2% in Chinese individuals >65 years old, accounting for 40% of the global total of PD patients. The pathogenesis of PD is not yet clear, and oxidative stress-induced mitochondrial dysfunction is considered to be the main reason for the onset of PD. Studies have shown that matrine exhibits good antioxidant activity. Thus, the present study aimed to observe the protective effect and mechanism of matrine on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuron damage...
January 2017: Oncology Letters
https://www.readbyqxmd.com/read/28104279/effect-of-inhibition-of-fatty-acid-amide-hydrolase-on-mptp-induced-dopaminergic-neuronal-damage
#20
J M Viveros-Paredes, R E Gonzalez-Castañeda, A Escalante-Castañeda, A R Tejeda-Martínez, F Castañeda-Achutiguí, M E Flores-Soto
INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative disorder characterised by balance problems, muscle rigidity, and slow movement due to low dopamine levels and loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The endocannabinoid system is known to modulate the nigrostriatal pathway through endogenous ligands such as anandamide (AEA), which is hydrolysed by fatty acid amide hydrolase (FAAH). The purpose of this study was to increase AEA levels using FAAH inhibitor URB597 to evaluate the modulatory effect of AEA on dopaminergic neuronal death induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)...
January 16, 2017: Neurología: Publicación Oficial de la Sociedad Española de Neurología
keyword
keyword
66495
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"